DDX56 and hepatocellular carcinoma: It has been reported that DDX56 could transcriptionally activate MIST1 to facilitate tumorigenesis of HCC through the PTEN/AKT signalling pathway [9]; DDX1 could inhibit CD8+ T cell antitumour activity by inducing PD‐L1 expression in HCC [10].